Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in capsular contracture research.
|Videos|April 23, 2018
Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
Author(s)Elizabeth Swisher, MD
In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in breast cancer, and the importance of understanding how resistance to these agents develops.
Advertisement
In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops.
Advertisement
Related to this article
Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.
Leah Katz, MD, MPH, discusses IDEA, TARGIT-B, NeoORB, and other breast radiation data from ASTRO 2026, and why patient selection is the unifying theme.
Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs
2
Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC
3
Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC
4
The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery
5